WESTON, FL – ParinGenix, which is developing a modified form of heparin to reduce inflammation in patients following a heart attack, has nabbed $4.39 million of a $5 million equity funding, according to a regulatory filing.
Investors in the company, which disclosed the raise in a filing with the U.S. Securities and Exchange Commission, include Investors Research Corp. Technologies, (RCT) of Tuson, AZ, Academy Venture Fund of Charlotte, NC, A.P. Kennedy Family Securities of Madisonville, LA, CHL Medical Partners, Stamford, CT, Domain Associates, Princeton, NJ, and Aurora Funds, NC.
It raised a $4 million A round in 2002 and a $20.4 million B round in 2006.
Previously KRCT Therapeutics Inc., ParinGenix has developed a form of heparin that significantly reduces damage to the heart following myocardial infarction. It’s lead drug, PGX-100, is also in clinical trials for other critical-care indications.
- HyperBranch Medical Technologies lands $1.66M round
- Clarabridge connects with $4.25M financing for text analytics
- Durham-based Argos Therapeutics near close on $6M raise
- nContact Surgical grabs nearly $5M of $15M round
- CardioMems secures $22.1M of $29.5M raise
© 2010, TechJournal. All rights reserved.